Hong Liu-Seifert

TL;DR: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with mild Alzheimer's disease.

TL;DR: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline and the secondary outcomes were considered to be descriptive and are reported without significance testing.

TL;DR: Two identically designed placebo‐controlled phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding soluble amyloid‐β peptide, on cognitive and functional decline over 80 weeks in patients with mild‐to‐moderate Alzheimer's disease (AD).

TL;DR: Duloxetine was superior to placebo on the primary efficacy measure (weekly mean 24‐h pain scores) beginning at Week 1 and continuing through the treatment period (P ⩽ .05), and there was a significant improvement in the WOMAC physical functioning subscale and several other secondary outcomes.

TL;DR: IXE was superior to ADA in achievement of simultaneous improvement of joint and skin disease (ACR50 and PASI100) in patients with PsA and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).